NASDAQ:IDYA IDEAYA Biosciences Q4 2025 Earnings Results & Report $27.40 -2.96 (-9.75%) Closing price 04:00 PM EasternExtended Trading$26.70 -0.70 (-2.55%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. IDEAYA Biosciences beat analyst expectations on both earnings and revenue in its Q4 2025 results, released February 17, 2026. The company reported EPS of -$0.94 versus the -$1.03 consensus estimate, while revenue of $10.88 million topped the $5.95 million estimate by $4.93 million. Revenue increased 55.7% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 17, 2026TimeBefore Market OpensConference Call6:00 AM ET IDEAYA Biosciences EPS ResultsActual EPS-$0.94Consensus EPS -$1.03Beat/MissBeat by +$0.09One Year Ago EPS-$1.49EPS Beat Rate2 of last 8 quartersIDEAYA Biosciences Revenue ResultsActual Revenue$10.88 millionExpected Revenue$5.95 millionBeat/MissBeat by +$4.93 millionYoY Revenue Growth+55.70%Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) IDEAYA Biosciences Q4 2025 Earnings FAQ Did IDEAYA Biosciences beat earnings estimates for Q4 2025? IDEAYA Biosciences (NASDAQ:IDYA) reported earnings of -$0.94 per share for Q4 2025, beating the consensus estimate of -$1.03. The report was announced on Tuesday, February 17, 2026. What was IDEAYA Biosciences' revenue for Q4 2025? IDEAYA Biosciences reported revenue of $10.88 million for Q4 2025, against a consensus estimate of $5.95 million. IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 17 at 10:02 AM | seekingalpha.comIDEAYA Gains FDA Alignment On Registrational Trial Designs Of IDE849 For Neuroendocrine CarcinomasNovember 17 at 10:02 AM | rttnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 17 at 1:00 AM | Base Camp Trading (Ad)IDEAYA Biosciences (IDYA) vs. The Competition Financial SurveyNovember 17 at 2:33 AM | americanbankingnews.comTranscript : IDEAYA Biosciences, Inc. - Special CallNovember 16 at 6:37 PM | marketscreener.comMIDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a ...November 16 at 6:37 PM | finance.yahoo.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations. These candidates remain under clinical investigation; IDEAYA does not sell approved medicines. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and advances clinical development programs, including through collaborations with other biotechnology and pharmaceutical companies. Yujiro S. Hata is the company’s chief executive officer.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.